US 12,291,719 B2
Heterologous targeting peptide grafted AAVs
Miguel Sena Esteves, Worcester, MA (US); and Sourav Roy Choudhury, Worcester, MA (US)
Assigned to University of Massachusetts, Westborough, MA (US)
Filed by University of Massachusetts, Westborough, MA (US)
Filed on Apr. 22, 2021, as Appl. No. 17/237,095.
Application 17/237,095 is a continuation of application No. 16/451,049, filed on Jun. 25, 2019, granted, now 11,014,976.
Application 16/451,049 is a continuation of application No. 15/516,582, granted, now 10,370,432, previously published as PCT/US2015/053798, filed on Oct. 2, 2015.
Claims priority of provisional application 62/059,738, filed on Oct. 3, 2014.
Prior Publication US 2021/0324044 A1, Oct. 21, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/864 (2006.01); A61K 48/00 (2006.01); C07K 7/00 (2006.01); C07K 7/04 (2006.01); C07K 14/005 (2006.01); C07K 14/775 (2006.01); C07K 16/00 (2006.01); C12N 15/79 (2006.01); C12N 15/85 (2006.01); C12N 15/86 (2006.01); C07K 14/00 (2006.01); C07K 14/075 (2006.01); C07K 19/00 (2006.01)
CPC C12N 15/8645 (2013.01) [A61K 48/0025 (2013.01); A61K 48/0058 (2013.01); C07K 7/00 (2013.01); C07K 7/04 (2013.01); C07K 14/005 (2013.01); C07K 14/775 (2013.01); C07K 16/00 (2013.01); C12N 15/79 (2013.01); C12N 15/85 (2013.01); C12N 15/86 (2013.01); C07K 14/00 (2013.01); C07K 14/075 (2013.01); C07K 19/00 (2013.01); C07K 2319/01 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2310/141 (2013.01); C12N 2750/14145 (2013.01); C12N 2810/85 (2013.01)] 17 Claims
 
1. A method for delivering a transgene to a subject comprising:
administering a rAAV to a subject, wherein the rAAV comprises:
(i) a capsid protein having an N-terminally grafted heterologous targeting peptide, wherein:
(a) the capsid protein is a VP2 capsid protein that is not of an AAV2 serotype; and
(b) the targeting peptide is a CNS-targeting polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 5, that is inserted between the first and second amino acid residues of the VP2 capsid protein, and
(ii) a recombinant AAV vector comprising a transgene,
wherein the rAAV infects cells of a target tissue of the subject.